Collaboration between all stakeholders is needed
Regulators, payers, HTA agencies and payers are all interested in different aspects of a technology. As a result, early dialogue is important to ensure that the data to be collected will meet expectations and needs from all stakeholders.
Because of the complexities and barriers that we discussed in the other sections of the report, early collaboration between all stakeholders is needed to make sure plans are in place to limit delays in access. Companies, regulators, HTA agencies, payers as well as patients and clinicians all need a seat at the table.
There is a lack of evidence and information for policymakers around gene therapies and how processes can be adapted to accommodate them.
Informing and engaging policymakers on gene therapies will be important. It will be particularly important where barriers to adoption require legislative or policy changes.
